8-K: Strata Skin Sciences Announces 1-for-10 Reverse Stock Split to Meet Nasdaq Listing Requirements

Strata Skin Sciences will implement a 1-for-10 reverse stock split effective June 6, 2024, to comply with Nasdaq's minimum bid price rule.

Summary

• Strata Skin Sciences has announced a 1-for-10 reverse stock split of its common stock.
• The reverse stock split will be effective at 11:59 p.m. Eastern Time on June 6, 2024.
• The company's stock will begin trading on a split-adjusted basis on June 7, 2024, under the existing symbol SSKN but with a new CUSIP number.
• This action is primarily to meet Nasdaq's minimum bid price requirement for continued listing.
• Shareholders had previously approved a reverse split proposal between 1-for-5 and 1-for-25 on October 26, 2023.
• The company had until June 6, 2024, to trade above $1.00 per share before being compelled to move forward with the reverse split.
• The announcement of the 1-for-10 ratio fulfills the requirement to announce the proposed ratio by April 26, 2024.

Sentiment

Score: 3

Explanation: The announcement of a reverse stock split is generally viewed negatively by investors as it indicates a low share price and potential financial difficulties. While necessary for compliance, it does not reflect positive business performance.

Positives

• The company is taking action to maintain its Nasdaq listing.
• The reverse stock split will not alter any stockholder's percentage interest in the company's equity.
• Stockholders holding fractional shares will receive cash equal to the value of the fractional share.

Negatives

• The reverse stock split indicates the company's share price was below the Nasdaq minimum bid price requirement.
• The reverse stock split may be perceived negatively by some investors.

Risks

• The company's share price may continue to be volatile.
• There is no guarantee that the reverse stock split will ensure long-term compliance with Nasdaq listing requirements.
• The company faces risks related to financial, economic, business, competitive, market, and regulatory factors.

Future Outlook

The company's future performance is subject to various uncertainties, including financial, economic, business, competitive, market, and regulatory factors. The company does not undertake any obligation to update or revise forward-looking statements.

Management Comments

• Dr. Dolev Rafaeli, the company's Vice-Chairman and CEO, stated that the reverse split was necessary to comply with Nasdaq's minimum bid price rule.
• Dr. Rafaeli also noted that the announcement of the 1-for-10 ratio fulfills the requirement from the shareholder approval.

Industry Context

Reverse stock splits are a common action for companies facing delisting from major exchanges due to low share prices. This action is not unique to Strata Skin Sciences and is often a measure to regain compliance with listing requirements.

Comparison to Industry Standards

• Many companies facing similar listing issues have implemented reverse stock splits to maintain their exchange listing.
• The 1-for-10 ratio is within the typical range for reverse stock splits, which can vary widely depending on the company's specific circumstances.
• Other companies in the medical technology sector have also faced similar challenges with maintaining share price compliance.

Stakeholder Impact

• Shareholders will see a reduction in the number of shares they own, but their percentage ownership will remain the same.
• Shareholders holding fractional shares will receive cash payments.
• The company's ability to maintain its Nasdaq listing is important for investor confidence.

Next Steps

• The company will implement the 1-for-10 reverse stock split on June 6, 2024.
• The company's stock will begin trading on a split-adjusted basis on June 7, 2024.
• Stockholders will receive information from the company's transfer agent regarding their stock ownership following the reverse stock split.

Key Dates

Keywords

reverse stock split, Nasdaq, minimum bid price, SSKN, stock listing, shareholders, equity, compliance